Magazine:

krebs:hilfe!

Another shot at golden hour of my favorite city skyline. Chicago in his glory!

ASCO 2019: Individualized care in focus

As this year’s ASCO Annual Meeting draws near, we provide an outlook of the world’s largest oncology meeting in 2019. As always, we will report directly and on-site.

Sagittal plane of MRI brain image is background, Medical concept

Immunochemotherapy

AACR 2019: Pembrolizumab combined with chemotherapy improves survival of patients with NSCLC with brain and liver metastases

With the KEYNOTE-189 study, combined immunochemotherapy became the new first-line standard for metastastatic nonsquamous non-small-cell lung cancer. A recent update of the trial now reveals that patients with brain or liver metastasis benefit as well as patients without metastases.

Natural killer cells are a type of lymphocytes which destroy cancer cells and other altered cells releasing cytotoxic granules.

Immunotherapy combination

AACR 2019: Combined inhibition of TIM-3 and PD-L1 in advanced solid tumors

Current studies evaluate the potency of immunotherapy combinations to improve response rates and prevent resistance to monotherapy treatment. Now, current data of an ongoing phase I/II trial evaluating combined TIM-3/PD-1 inhibition were presented.

Speakers & Attendees during Opening Plenary: Forging Ahead towards Improved and Equitable Patient Care through Precision and Convergent Cancer Science

Experimental immunotherapy

AACR 2019: Immunotherapy with bintrafusp alfa shows efficacy for HPV-associated tumors

For human papillomavirus associated tumors, standard chemotherapy regimens show only limited efficacy. An ongoing phase I trial evaluating immunotherapy M7824 delivered encouraging data.

Closeup kid hand sleeps on a bed in hospital with saline intravenous, selective focus.

AACR 2019: Genetic risk factor for strokes following cranial radiation therapy for childhood cancers identified

It has been long known that radiation increases the risk of cancer survivors for strokes. That – and which – genetic features can further enhance the specific risk, a study shows.

Advertising

Human Body Organs Anatomy (Pancreas)

AACR 2019: Successful maintenance therapy for BRCA-/PALB2-mutated pancreatic cancer

Results of a phase II clinical trial suggest that the PARP inhibitor rucaparib can stabilize and in some instances even improve disease of patients with somatic or germ line mutations of BRCA1, BRCA2 or PALB2.

Gerhard_Emrich_small

AACR 2019: Gilteritinib improves survival of patients with acute myeloid leukemia

Treatment with the next-generation FLT3 inhibitor gilteritinib improved survival of patients with relapsed/refractory acute myeloid leukemia (AML) compared to standard chemotherapy.

Attendees during General Views

marginal zone lymphoma

AACR 2019: 91% of patients with marginal zone lymphoma respond to umbralisib

Umbralisib, a small-molecule inhibitor that targets PI3K-delta, is safe and efficacious for patients with relapsed/refractory marginal zone lymphoma. This an interim analysis of the phase II clinical trial UNITY-NHL shows.

Attendees during General Views

Immuno-Oncology

AACR 2019: Patients with high-grade neuroendocrine carcinoma benefit from immune checkpoint inhibitor combination

Results from a phase II clinical trial presented at the AACR Annual Meeting 2019 demonstrate that the combination of nivolumab and ipilimumab could be efficacious in high-grade neuroendocrine carcinoma.

Atlanta is the capital and most populated city of the US state of Georgia. Its Downtown District is specially charming at sunset

AACR 2019: What Atlanta has to offer for oncology specialists this year

From Friday, March 29, to Tuesday, April 3, 2019, the 110th American Association for Cancer Research (AACR) Annual Meeting will take place in Atlanta (Georgia). medonline will be reporting directly from the congress.

Eine Abbildung des Logos vom ESMO-Kongress.

Congress summary

ESMO 2018: 55 take-home messages

"A congress after which we have to change our practice," was the conclusion of many experts interviewed by the medonline team during ESMO 2018. Here, we summarize their highlights from the congress.

This was ASCO 2018

This was ASCO 2018

Univ.-Prof. Dr. Shahrokh Shariat, Universitätsklinik für Urologie, Wien

Breakfast Brief with Univ.-Prof. Dr. Shahrokh F. Shariat

Univ.-Prof. Dr. Shahrokh F. Shariat, Chairman at the Department of Urology, Medical University Vienna, presents the most relevant urothelial carcinoma studies of ASCO Congress 2018.

Cancer cell. Oncology, research, structure. mutation, somatic cell of the body. genetic predisposition. Neoplasms, cancerous disease, malignant tumour. Danger, fear, the unknown

Pembrolizumab plus Chemotherapy as first-line treatment of metastatic squamous NSCLC

New Data suggest Pembrolizumab plus Chemotherapy should become a new standard-of-care for first-line treatment of metastatic squamous NSCLC, irrespective of PD-L-1 expression.

Breakfast Brief Prof. Rothschild

breakfast brief

Breakfast Brief with PD DDr. Sacha Rothschild

In this Breakfast Brief, PD DDr. Sacha Rothschild presents his Immuno-Oncology highlights of the first two days of ASCO Congress 2018

Olivier Breakfast Brief

Breakfast Brief Prof. Olivier Michielin – Related Abstracts

George Paul Breakfast Breif

Breakfast Brief Dr. Pall – Related Abstracts

Reinhard and Christoph Interview FULL

Christoph Höller (AT) and Reinhard Dummer (CH) on melanoma

Christoph Höller (AT) and Reinhard Dummer (CH) on melanoma